NN
NNBP.US Nanobac Pharmaceuticals Incorporated
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2007.
Is NNBP.US undervalued?
Graham numberThe Graham number of Nanobac Pharmaceuticals Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanobac Pharmaceuticals Incorporated fundamental analysis
No fundamental analysis for Nanobac Pharmaceuticals Incorporated yet.
Nanobac Pharmaceuticals Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanobac Pharmaceuticals Incorporated
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including c…
Full company profileNanobac Pharmaceuticals Incorporated financial statements
Nanobac Pharmaceuticals Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 12.0K | 483K | 358K | 657K | 225K | 17.6K |
| Gross Profit | 8.00K | 150K | 258K | 427K | 145K | 3.10K |
| Operating Income | - | - | -7.60M | -2.84M | -4.23M | -4.43M |
| Net Income | - | - | -8.52M | -3.69M | -4.97M | -6.58M |
| Balance Sheet | ||||||
| Total Assets | 5.00K | 8.24M | 9.68M | 8.97M | 7.82M | 7.22M |
| Total Liabilities | 346K | 9.05M | 3.57M | 6.51M | 9.14M | 9.58M |
| Shareholders' Equity | -341K | -806K | 6.11M | 2.46M | -1.31M | -2.36M |
| Cash & Short-term Investments | - | 50.0K | 17.9K | 8.98K | 39.5K | 3.93K |
| Cash Flow | ||||||
| Operating Cash Flow | - | - | -3.40M | -2.37M | -2.58M | -911K |
| Capital Expenditure | 0.00 | 18.0K | 36.8K | 40.6K | 12.8K | 1.53K |
| Ratios | ||||||
| ROE | - | - | -139.4% | -149.6% | - | - |
| ROA | - | - | -88.0% | -41.1% | -63.6% | -91.1% |
| Net Profit Margin | - | - | -2,377.0% | -561.4% | -2,209.5% | -37,319.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nanobac Pharmaceuticals Incorporated dividends
Nanobac Pharmaceuticals Incorporated has not paid dividends in the last 6 fiscal years.
Last stock split: 1:4 on Mar 27, 2000.
Who owns Nanobac Pharmaceuticals Incorporated
Ownership data of Nanobac Pharmaceuticals Incorporated is not available yet.
Nanobac Pharmaceuticals Incorporated company profile
- Company name
- Nanobac Pharmaceuticals Incorporated
- Ticker
- NNBP.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 3000 Bayport Drive, Tampa, FL, United States, 33607
- Phone
- 813-865-1125
- Website
- -
About Nanobac Pharmaceuticals Incorporated
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.
Nanobac Pharmaceuticals Incorporated management
4- Mr. John M. StantonChairman, CEO, CFO & Principal Accounting Officer · born 1963
- Mr. Benedict Salvadore Maniscalco M.D.Director of Clinical Research, Medical Director & Director · born 1942
- Dr. Neva CiftciogluCo-Founder, Director of Science & Scientific Advisor
- Dr. E. Olavi KajanderChief Science & Research Officer and MD of Nanobac OY